Headlands Research Acquires Eastern Massachusetts–Based Research Site


Headlands Research has announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease for over 25 years.

Headlands Research Eastern Massachusetts is led by founder and Principal Investigator (PI) Donald Marks, MD, a board-certified neurologist specializing in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and related disorders who also currently serves on the staff of the Division of Neurology at Beth Israel Deaconess Hospital—Plymouth. Marks conducted his first clinical trial in 1993, evaluating tacrine, the first drug approved for the treatment of Alzheimer’s disease, and in 2008, Marks and his team began research on disease-modifying drugs (DMDs) for Alzheimer’s disease. To date, Marks and his team have conducted 41 clinical trials, with 36 focusing on Alzheimer’s disease. The team has been in an accelerated growth phase—13 of the 36 Alzheimer’s disease trials have been started since 2020.


Headlands Research Acquires Established Eastern Massachusetts–Based Research Site Specializing in Neurodegenerative Diseases. (2023, April 18). Business Wire.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.